A multi-centered trial investigating gestational treatment with ursodeoxycholic acid compared to metformin to reduce effects of diabetes mellitus (GUARD): a randomized controlled trial protocol.
Blood Glucose
Diabetes Mellitus, Type 2
/ diagnosis
Diabetes, Gestational
/ diagnosis
Female
Glucose
/ therapeutic use
Humans
Infant, Newborn
Metformin
/ adverse effects
Multicenter Studies as Topic
Pregnancy
Premature Birth
Randomized Controlled Trials as Topic
Ursodeoxycholic Acid
/ adverse effects
Gestational diabetes mellitus
Metformin
Randomized clinical trial
Treatment
Ursodeoxycholic acid
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
19 Jul 2022
19 Jul 2022
Historique:
received:
15
03
2022
accepted:
09
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Each year in the UK, approximately 35,000 women develop gestational diabetes mellitus (GDM). The condition increases the risk of obstetric and neonatal complications for mother and child, including preeclampsia, preterm birth, and large for gestational age babies. Biochemical consequences include maternal hyperglycemia, neonatal hypoglycemia, and dyslipidemia. Metformin is the most commonly used firstline pharmacological treatment. However, there are concerns about its widespread use during pregnancy, due to its limited efficacy and potential safety concerns. Therefore, there is a need for additional therapies that improve both maternal-fetal glucose and lipid metabolism. Ursodeoxycholic acid (UDCA) is not currently used for treatment for GDM. However, it can improve glucose control in type 2 diabetes, and it improves fetal lipid profiles in gestational cholestasis. Consequentially, it is hypothesized that treatment with UDCA for women with GDM may improve both maternal metabolism and neonatal outcomes. The primary outcome of this trial is to assess the efficacy of UDCA compared with metformin to improve glucose levels in women with GDM. The trial is a two-armed, open-label, multi-center, randomized controlled trial. Women are eligible if they have been diagnosed with GDM by an oral glucose tolerance test between 24 + 0 and 30 + 6 weeks' gestation, and if they require pharmacological intervention. In total, 158 pregnant women will be recruited across seven NHS Trusts in England and Wales. Women who consent will be recruited and randomized to either metformin or UDCA, which will be taken daily until the birth of their baby. Maternal and neonatal blood samples will be taken to evaluate the impact of the treatments on maternal glucose control, and maternal and neonatal lipid metabolism. Maternal and fetal outcomes will be evaluated, and acceptability of UDCA compared with metformin will be assessed. This trial has the potential to identify a potential new treatment for women with GDM. If successful, a future large multi-center trial will be designed to investigate where decisions can be personalized to identify which women will respond more effectively to UDCA than alternatives to improve maternal and baby outcomes. ClinicalTrials.gov NCT04407650.
Sections du résumé
BACKGROUND
BACKGROUND
Each year in the UK, approximately 35,000 women develop gestational diabetes mellitus (GDM). The condition increases the risk of obstetric and neonatal complications for mother and child, including preeclampsia, preterm birth, and large for gestational age babies. Biochemical consequences include maternal hyperglycemia, neonatal hypoglycemia, and dyslipidemia. Metformin is the most commonly used firstline pharmacological treatment. However, there are concerns about its widespread use during pregnancy, due to its limited efficacy and potential safety concerns. Therefore, there is a need for additional therapies that improve both maternal-fetal glucose and lipid metabolism. Ursodeoxycholic acid (UDCA) is not currently used for treatment for GDM. However, it can improve glucose control in type 2 diabetes, and it improves fetal lipid profiles in gestational cholestasis. Consequentially, it is hypothesized that treatment with UDCA for women with GDM may improve both maternal metabolism and neonatal outcomes. The primary outcome of this trial is to assess the efficacy of UDCA compared with metformin to improve glucose levels in women with GDM.
METHODS
METHODS
The trial is a two-armed, open-label, multi-center, randomized controlled trial. Women are eligible if they have been diagnosed with GDM by an oral glucose tolerance test between 24 + 0 and 30 + 6 weeks' gestation, and if they require pharmacological intervention. In total, 158 pregnant women will be recruited across seven NHS Trusts in England and Wales. Women who consent will be recruited and randomized to either metformin or UDCA, which will be taken daily until the birth of their baby. Maternal and neonatal blood samples will be taken to evaluate the impact of the treatments on maternal glucose control, and maternal and neonatal lipid metabolism. Maternal and fetal outcomes will be evaluated, and acceptability of UDCA compared with metformin will be assessed.
DISCUSSION
CONCLUSIONS
This trial has the potential to identify a potential new treatment for women with GDM. If successful, a future large multi-center trial will be designed to investigate where decisions can be personalized to identify which women will respond more effectively to UDCA than alternatives to improve maternal and baby outcomes.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04407650.
Identifiants
pubmed: 35854327
doi: 10.1186/s13063-022-06462-y
pii: 10.1186/s13063-022-06462-y
pmc: PMC9295112
doi:
Substances chimiques
Blood Glucose
0
Ursodeoxycholic Acid
724L30Y2QR
Metformin
9100L32L2N
Glucose
IY9XDZ35W2
Banques de données
ClinicalTrials.gov
['NCT04407650']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
571Subventions
Organisme : Tommy's
ID : 81
Informations de copyright
© 2022. The Author(s).
Références
J Clin Endocrinol Metab. 2010 Dec;95(12):E448-55
pubmed: 20926533
PLoS One. 2018 Jan 12;13(1):e0190676
pubmed: 29329330
Diabetologia. 2017 Oct;60(10):1903-1912
pubmed: 28766127
Diabetes Care. 2017 Jan;40(1):109-116
pubmed: 27810989
Am J Obstet Gynecol. 2020 Aug;223(2):246.e1-246.e10
pubmed: 32017923
Lancet Diabetes Endocrinol. 2014 Jun;2(6):488-99
pubmed: 24731659
Diabetes Care. 2011 Oct;34(10):2279-84
pubmed: 21949222
Eur Heart J. 2010 Aug;31(15):1865-71
pubmed: 20197424
BJOG. 2013 May;120(6):717-23
pubmed: 23418899
Acta Obstet Gynecol Scand. 2010 May;89(5):700-4
pubmed: 20423280
Aust N Z J Obstet Gynaecol. 2007 Feb;47(1):37-41
pubmed: 17261098
Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S64-9
pubmed: 12324988
Diabetes Care. 2015 Feb;38(2):243-8
pubmed: 25504029
Diabet Med. 1994 Jun;11(5):510-6
pubmed: 8088133
N Engl J Med. 2008 May 8;358(19):1991-2002
pubmed: 18463375
Am J Clin Nutr. 2008 Oct;88(4):894-9
pubmed: 18842773
Microbiome. 2018 May 15;6(1):89
pubmed: 29764499
BJOG. 2015 Apr;122(5):643-51
pubmed: 25612005
Clin Sci (Lond). 2012 Jan;122(2):53-61
pubmed: 21745185
Ann Hepatol. 2004 Jul-Sep;3(3):108-12
pubmed: 15505596
Pharmacol Res. 2018 Sep;135:144-149
pubmed: 30099154
Cochrane Database Syst Rev. 2018 Aug 14;8:CD012327
pubmed: 30103263
Lancet. 2019 Sep 7;394(10201):849-860
pubmed: 31378395
N Engl J Med. 2000 Oct 19;343(16):1134-8
pubmed: 11036118
Ultrasound Obstet Gynecol. 2019 May;53(5):638-648
pubmed: 29380922
Diabetes Care. 2007 Nov;30(11):2785-91
pubmed: 17666464
Diabetes Care. 2003 Apr;26(4):1199-205
pubmed: 12663597
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Acta Diabetol. 2018 Oct;55(10):1037-1042
pubmed: 29936651
Diabetes. 2009 Jul;58(7):1509-17
pubmed: 19366864
Diabetes Care. 2011 Oct;34(10):2198-204
pubmed: 21775754
Lancet. 1987 Dec 5;2(8571):1300-4
pubmed: 2890903
Sci Rep. 2020 Mar 3;10(1):3895
pubmed: 32127609
PLoS One. 2014 Sep 03;9(9):e103217
pubmed: 25184286
Circulation. 2002 Oct 15;106(16):2085-90
pubmed: 12379578
JAMA Intern Med. 2017 Dec 1;177(12):1735-1742
pubmed: 29049820
N Engl J Med. 2008 May 8;358(19):2003-15
pubmed: 18463376
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1612-1621
pubmed: 29490031
Diabetes Ther. 2018 Oct;9(5):1811-1829
pubmed: 30168045
Am J Obstet Gynecol. 2018 Oct;219(4):367.e1-367.e7
pubmed: 29959933
Diabetes Care. 2008 Sep;31(9):1858-63
pubmed: 18606978
BMJ. 2011 Feb 07;342:d40
pubmed: 21300711
Sci Rep. 2020 Jun 25;10(1):10361
pubmed: 32587408
Pharmacoeconomics. 2018 Jun;36(6):645-661
pubmed: 29572719
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Am J Obstet Gynecol. 2018 Feb;218(2S):S609-S618
pubmed: 29422203
J Am Coll Cardiol. 2014 Feb 25;63(7):636-646
pubmed: 24239664
BMJ Open Diabetes Res Care. 2018 Mar 17;6(1):e000469
pubmed: 29607050
JAMA. 2018 Sep 11;320(10):1005-1016
pubmed: 30208453
Cell. 2012 Aug 3;150(3):470-80
pubmed: 22863002
Diabetes Care. 2010 Dec;33(12):2524-30
pubmed: 20843973
Br J Cancer. 2016 Dec 6;115(12):1451-1456
pubmed: 27875520
Diabetologia. 2011 Jul;54(7):1670-5
pubmed: 21494772
Am J Obstet Gynecol. 2017 Sep;217(3):282-302
pubmed: 28619690
Int J Behav Nutr Phys Act. 2016 Nov 29;13(1):124
pubmed: 27894316
BMC Pregnancy Childbirth. 2017 Sep 22;17(1):316
pubmed: 28938877
Biometrics. 1987 Mar;43(1):213-23
pubmed: 3567306